Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.500 -0.100 (-2.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
News headline image
Altimmune: Q1 Earnings Insights ↗
Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Altimmune: Q4 Earnings Insights ↗
Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Altimmune's Earnings Outlook ↗
Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
B. Riley Securities Maintains Buy Rating for Altimmune: Here's What You Need To Know ↗
  B. Riley Securities has decided to maintain its Buy rating of Altimmune (NASDAQ:ALT) and raise its price target from $21.00 to $26.00. Shares of Altimmune are trading up 23.53% over the last 24... 
Via Benzinga
News headline image
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday ↗
  WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
  
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Q3 ↗
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
News headline image
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity ↗
The FDA has cleared Altimmune Inc's (NASDAQ: 
Via Benzinga
News headline image
89 Biggest Movers From Friday ↗
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
69 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
News headline image
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know ↗
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24... 
Via Benzinga
News headline image
110 Biggest Movers From Friday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
News headline image
Altimmune Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For March 14, 2022 ↗
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX 
Via Benzinga
News headline image
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street ↗
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
News headline image
ALTIMMUNE INC (ALT) Q3 2021 Earnings Call Transcript ↗
ALT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
52 Biggest Movers From Yesterday ↗
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
News headline image
33 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... 
Via Benzinga
News headline image
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off ↗
H.C. Wainwright said that Altimmune Inc (NASDAQ: 
Via Benzinga
News headline image
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34 ↗
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock. 
Via InvestorPlace
News headline image
Dow Set to Snap Win Streak as Tech Sector Weighs ↗
The Dow Jones Industrial Average looks ready to snap its four-day win streak, as the tech sector's recent rout catches up with the index, which was last seen down 419 points. 
Via Talk Markets
Topics Stocks
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.